NDC 64038-139 - Cyclo/Mag 10mg/200mg
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 64038-139
- Package NDCs from labels
- 64038-139-60
- Manufacturer
- Living Well Pharmacy, Inc. | Apotheca Supply | Spectrum Laboratory Products, Inc.
- Effective date
- 2010-02-17
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| CYCLO/MAG KIT | Living Well Pharmacy, Inc. | Apotheca Supply | Spectrum Laboratory Products, Inc. | 2010-02-17 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 64038-139-60 | Cyclo/Mag 10mg/200mg | 60 g in 1 BOTTLE | POWDER | 60 g | 1 g in 1g | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| CYCLOBENZAPRINE HYDROCHLORIDE | ACTIVE INGREDIENT | 0VE05JYS2P | CYCLO/MAG 10MG/200MG (CYCLOBENZAPRINE HYDROCHLORIDE, MAGNESIUM OXIDE) KIT [LIVING WELL PHARMACY, INC.] | 1 | |
| MAGNESIUM OXIDE | ACTIVE INGREDIENT | 3A3U0GI71G | CYCLO/MAG 10MG/200MG (CYCLOBENZAPRINE HYDROCHLORIDE, MAGNESIUM OXIDE) KIT [LIVING WELL PHARMACY, INC.] | 1 | |
| CYCLOBENZAPRINE | ACTIVE MOIETY | 69O5WQQ5TI | CYCLO/MAG 10MG/200MG (CYCLOBENZAPRINE HYDROCHLORIDE, MAGNESIUM OXIDE) KIT [LIVING WELL PHARMACY, INC.] | 1 | |
| MAGNESIUM OXIDE | ACTIVE MOIETY | 3A3U0GI71G | CYCLO/MAG 10MG/200MG (CYCLOBENZAPRINE HYDROCHLORIDE, MAGNESIUM OXIDE) KIT [LIVING WELL PHARMACY, INC.] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Advanced Rx of Tennessee, LLC | 30ca08c7-4ee3-2f37-e063-6294a90ae31a | 2025-03-20 | Warnings, Adverse reactions | 0VE05JYS2P |
| Vitafol Ultra | DOCONEXENT, NIACINAMIDE, .ALPHA.-TOCOPHEROL ACETATE, DL-, CHOLECALCIFEROL, .BETA.-CAROTENE, ASCORBIC ACID, THIAMINE MONONITRATE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE, CYANOCOBALAMIN, IRON, ZINC OXIDE, CUPRIC OXIDE, POTASSIUM IODIDE, MAGNESIUM OXIDE, FOLIC ACID, AND LEVOMEFOLATE CALCIUM | Exeltis USA, Inc. | 40fa2c3a-f41f-434c-91de-5150a18d3e4b | 2025-03-13 | Boxed warning, Warnings, Adverse reactions | 3A3U0GI71G |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Jubilant Cadista Pharmaceuticals Inc. | 592871f6-0eb2-4624-9e10-bd8bf767c002 | 2025-02-21 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Rising Pharma Holdings, Inc. | 6018b6e9-938d-4fc9-86d7-1fd1d7bfcc58 | 2025-02-20 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Upsher-Smith Laboratories, LLC | 14f64ceb-ea5c-4d7c-a0c1-3f6a64847290 | 2025-02-20 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | aa29e260-fb77-415a-a505-3230d30c8945 | 2025-02-10 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | fbd38abb-02ae-1a36-e053-6294a90abe65 | 2025-02-04 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 418e3974-f7dd-4f27-bee5-3c2fb0531c4c | 2025-02-03 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | 05641925-7b10-4b30-b6e8-44b416a5e77e | 2025-02-03 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | 96207b29-033b-46a3-961f-e5125288d50f | 2025-02-03 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Redpharm Drug, Inc. | 09d0e2fc-76a4-bb7d-e063-6394a90a4a7d | 2025-01-23 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Redpharm Drug | fc61c9f5-b0ec-3ff8-e053-6394a90adeb7 | 2025-01-23 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Redpharm Drug | 09d35c34-11fa-3a5d-e063-6294a90ab172 | 2025-01-23 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine HCL ER | CYCLOBENZAPRINE HCL ER | Direct_Rx | e4a3383a-7b30-25b7-e053-2995a90a341b | 2025-01-22 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine HCL ER | CYCLOBENZAPRINE HCL ER | Direct_Rx | ed0b9acc-132f-64c0-e053-2995a90a198c | 2025-01-22 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | DirectRx | ceb56ab8-4a76-6dee-e053-2995a90aab30 | 2025-01-20 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | DIRECT RX | a58cf759-048b-6740-e053-2a95a90a8b43 | 2025-01-17 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | DIRECT RX | a512d34c-8164-0c04-e053-2995a90a1942 | 2025-01-17 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | 01e18825-1cf9-a98c-e063-6294a90ae0a4 | 2025-01-14 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 3dd2bde1-f06d-493a-91c7-22b28a5e1699 | 2025-01-07 | Warnings, Adverse reactions | 0VE05JYS2P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.